Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Apogee Therapeutics, Inc. - Common Stock (NQ: APGE )

37.47 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 37.47
Bid (Size) 14.99 (2)
Ask (Size) 39.00 (1)
Prev. Close 37.47
Today's Range 37.47 - 37.47
52wk Range 14.19 - 72.29
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Apogee Therapeutics Expands Board of Directors with the Appointment of Lisa Bollinger, MD
From Apogee Therapeutics, LLC
Via GlobeNewswire
Apogee Therapeutics to Participate in Upcoming June Investor Conferences
From Apogee Therapeutics, LLC
Via GlobeNewswire

Performance

YTD
+31.43%
+31.43%
1 Month
-21.71%
-21.71%
3 Month
-42.99%
-42.99%
6 Month
+20.60%
+20.60%
1 Year
+76.50%
+76.50%

More News

Read More
Apogee Announces Dosing of First Patient in Phase 2 Atopic Dermatitis Trial of APG777, a Novel Subcutaneous Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases
From Apogee Therapeutics, LLC
Via GlobeNewswire
APGE Stock Earnings: Apogee Therapeutics Misses EPS for Q1 2024
Via InvestorPlace
Apogee Therapeutics Highlights Pipeline Progress and Reports First Quarter 2024 Financial Results
From Apogee Therapeutics, LLC
Via GlobeNewswire
Earnings Superstars: 3 Stocks Primed to Outperform This Quarter
Via InvestorPlace
Apogee Therapeutics to Participate at the 2024 Bank of America Healthcare Conference
From Apogee Therapeutics, LLC
Via GlobeNewswire
Apogee Therapeutics Announces First Participants Dosed in Phase 1 Trial of APG808, its Novel Half-life Extended IL-4Rα Antibody for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) and Other Inflammatory Diseases
From Apogee Therapeutics, LLC
Via GlobeNewswire
Top 3 Health Care Stocks That Are Ticking Portfolio Bombs
Via Benzinga
Apogee Therapeutics, Inc. Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $483 Million
From Apogee Therapeutics, LLC
Via GlobeNewswire
Apogee Therapeutics, Inc. Announces Pricing of Upsized $420 Million Underwritten Public Offering
From Apogee Therapeutics, LLC
Via GlobeNewswire
APGE Stock Earnings: Apogee Therapeutics Beats EPS for Q4 2023
Via InvestorPlace
Apogee Therapeutics, Inc. Announces Proposed Underwritten Public Offering
From Apogee Therapeutics, LLC
Via GlobeNewswire
Crude Oil Down 1%; Dave Shares Jump After Q4 Results
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
Why SOPHiA GENETICS Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Nasdaq Down 250 Points; ISM Services PMI Falls In February
Via Benzinga
Topics Stocks
Exposures US Equities
Why Is Atopic Dermatitis-Focused Apogee Therapeutics Stock Trading Higher On Tuesday?
Via Benzinga
NIO Reports Upbeat Earnings, Joins Dave, V2X, Riskified And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Topics Stocks
Exposures US Equities
Dow Dips Over 100 Points; Target Posts Upbeat Earnings
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
IPO Stock Apogee Shifts Higher On Solid Phase 1 Outcome
Via Investor's Business Daily
Topics Initial Public Offering
Exposures Securities Market
Apogee Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial Results
From Apogee Therapeutics, LLC
Via GlobeNewswire
Apogee Announces Positive Interim Results from Phase 1 Healthy Volunteer Trial for APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases, Exceeding its Trial Objectives Ahead of
From Apogee Therapeutics, LLC
Via GlobeNewswire
Apogee to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trial for APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases on March 5, 2024
From Apogee Therapeutics, LLC
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.